Suppression of Calpain Attenuates Coxsackievirus B3-Induced Myocarditis by Regulating RIPK1/RIPK3/MLKL Pathway.

IF 2.6 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Yuxi Liu, Yong Wang, Guijian Liu, Fei Yi, Dongyang Che, Zhiwei Chen, Yunzeng Zou, Ruizhen Chen
{"title":"Suppression of Calpain Attenuates Coxsackievirus B3-Induced Myocarditis by Regulating RIPK1/RIPK3/MLKL Pathway.","authors":"Yuxi Liu, Yong Wang, Guijian Liu, Fei Yi, Dongyang Che, Zhiwei Chen, Yunzeng Zou, Ruizhen Chen","doi":"10.1007/s12265-026-10744-0","DOIUrl":null,"url":null,"abstract":"<p><p>Viral myocarditis caused by CVB3 inflicts substantial myocardial damage and predisposes to heart failure. Although necroptosis contributes to disease progression, the mechanisms governing this death pathway during CVB3 infection remain unclear. We found that calpain and its inhibitor Cast were dynamically expressed during CVB3 infection, correlating with cardiac damage, inflammation, and fibrosis. Further investigation revealed that CVB3 dynamically induced cardiomyocyte necroptosis by activating the RIPK1/RIPK3/MLKL pathway, which was prominently activated in the early acute phase but potentially attenuated in later stages. Immunofluorescence analysis supported the translocation of p-MLKL from the nucleus to the plasma membrane during disease progression. Importantly, both in vivo and in vitro experiments supported that calpain inhibition ALLN attenuated VMC via the RIPK1/RIPK3/MLKL pathway, and improved cardiac function post-CVB3 infection. The calpain activator PMMA exacerbated this process. Our findings reveal that calpain inhibition attenuated VMC by modulating the RIPK1/RIPK3/MLKL pathway, uncovering a novel regulatory mechanism in VMC.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":"19 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619709/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-026-10744-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Viral myocarditis caused by CVB3 inflicts substantial myocardial damage and predisposes to heart failure. Although necroptosis contributes to disease progression, the mechanisms governing this death pathway during CVB3 infection remain unclear. We found that calpain and its inhibitor Cast were dynamically expressed during CVB3 infection, correlating with cardiac damage, inflammation, and fibrosis. Further investigation revealed that CVB3 dynamically induced cardiomyocyte necroptosis by activating the RIPK1/RIPK3/MLKL pathway, which was prominently activated in the early acute phase but potentially attenuated in later stages. Immunofluorescence analysis supported the translocation of p-MLKL from the nucleus to the plasma membrane during disease progression. Importantly, both in vivo and in vitro experiments supported that calpain inhibition ALLN attenuated VMC via the RIPK1/RIPK3/MLKL pathway, and improved cardiac function post-CVB3 infection. The calpain activator PMMA exacerbated this process. Our findings reveal that calpain inhibition attenuated VMC by modulating the RIPK1/RIPK3/MLKL pathway, uncovering a novel regulatory mechanism in VMC.

抑制Calpain通过调控RIPK1/RIPK3/MLKL通路减轻柯萨奇病毒b3诱导的心肌炎
由CVB3引起的病毒性心肌炎会造成严重的心肌损伤,并容易导致心力衰竭。尽管坏死性上睑下垂有助于疾病进展,但在CVB3感染期间控制这种死亡途径的机制尚不清楚。我们发现calpain及其抑制剂Cast在CVB3感染期间动态表达,与心脏损伤、炎症和纤维化相关。进一步研究发现,CVB3通过激活RIPK1/RIPK3/MLKL通路动态诱导心肌细胞坏死,该通路在急性早期显著激活,但在后期可能减弱。免疫荧光分析支持在疾病进展过程中p-MLKL从细胞核向质膜的易位。重要的是,体内和体外实验都支持calpain抑制ALLN通过RIPK1/RIPK3/MLKL途径减轻VMC,并改善cvb3感染后的心功能。钙蛋白酶激活剂PMMA加剧了这一过程。我们的研究结果表明,calpain抑制通过调节RIPK1/RIPK3/MLKL通路来减轻VMC,揭示了VMC的一种新的调控机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cardiovascular Translational Research
Journal of Cardiovascular Translational Research CARDIAC & CARDIOVASCULAR SYSTEMS-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
6.10
自引率
2.90%
发文量
148
审稿时长
6-12 weeks
期刊介绍: Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research. JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials. JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书